KR800000906B1 - Process for preparing homophthalimides - Google Patents

Process for preparing homophthalimides Download PDF

Info

Publication number
KR800000906B1
KR800000906B1 KR7601728A KR760001728A KR800000906B1 KR 800000906 B1 KR800000906 B1 KR 800000906B1 KR 7601728 A KR7601728 A KR 7601728A KR 760001728 A KR760001728 A KR 760001728A KR 800000906 B1 KR800000906 B1 KR 800000906B1
Authority
KR
South Korea
Prior art keywords
dimethyl
dioxo
isoquinolyl
dihydro
propyl
Prior art date
Application number
KR7601728A
Other languages
Korean (ko)
Inventor
쿠터 에베르하르트
아우스텔 폴크하르트
에베르라인 볼프강
하이더 요아힘
코빙거 발터
리리에 크리스티안
카다쯔 루돌프
Original Assignee
하인쯔 쉐프러 프리츠 좀머
닥터. 칼 토메 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인쯔 쉐프러 프리츠 좀머, 닥터. 칼 토메 게젤샤프트 filed Critical 하인쯔 쉐프러 프리츠 좀머
Priority to KR7601728A priority Critical patent/KR800000906B1/en
Application granted granted Critical
Publication of KR800000906B1 publication Critical patent/KR800000906B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antiarrhythmic title compds. (I; R1, R3=H, OMe, R2, R4=H, F, Br, Me, OMe; OEt, iso-propoxy, methylthio, NO2, amino, acetylamino; R5, R6, R7, R8=H, Me, Et, Pr, iso-propyl, Bu, C6H5, p-OMeC6H4, phenylpropyl; A, B=ethylene, 1-methylethylene, propylene, Bu, n-hexyl, C6H5, phenylethyl, phenylpropyl were prepd. Thus, reaction of 19 g(0.1 mol) 4, 4-dimethyl-isochromandion-1, 3 with CH3N(CH2CH2CH2NH2)2 in HO(CH2)2-OH at 180≰C, 4hr gives 65% I(R1, R2, R3, R4=H; R5, R6, R7, R8, R9=Me; A, B=Pr). EC50 and ED50 for I were 5.5 mg/ml and mg/kg in mice, resp.

Description

호모프탈이미드류의 제조방법Manufacturing Method of Homophthalimides

본 발명은 부정맥 치료에 유효한 작용을 갖는 다음 구조식 (I)화합물 및 이의 산부가염의 제조방법에 관한 것이다.The present invention relates to the following compound of formula (I) having an effective action in the treatment of arrhythmia and a method for preparing acid addition salts thereof.

Figure kpo00001
Figure kpo00001

상기 구조식에서In the above structural formula

A와 B는 메틸 또는 페닐그룹으로 임의로 치환된 탄소수 2 내지 4인 직쇄인 포화알킬렌그룹이며 같거나 다를 수 있고A and B are straight-chain saturated alkylene groups having 2 to 4 carbon atoms optionally substituted with methyl or phenyl groups and may be the same or different.

R1,R2,R3및 R4는 수소, 불소, 염소 또는 브롬, 하이드록시, 아미노, 니트로 또는 아세틸아미노, 알킬부분의 탄소수가 1내지 3인 알킬, 알콕시 또는 알킬티오그룹이며, 같거나 다를 수 있고R 1 , R 2 , R 3 and R 4 are hydrogen, fluorine, chlorine or bromine, hydroxy, amino, nitro or acetylamino, an alkyl, alkoxy or alkylthio group having 1 to 3 carbon atoms in the alkyl moiety Can be different

R5,R6,R7과 R8는 수소, 페닐 또는 메톡시페닐그룹으로 임의로 치환된 탄소수 1내지 4인 알킬이며, 같거나 다를 수 있고 R5는 R6와 함께, R7은 R8과 함께 탄소수 2내지 5인 직쇄인 포화 알킬렌그룹이고 R9은 수소 또는 페닐로 임의로 치환된 탄소수 1내지 6인 알킬이다.R 5 , R 6 , R 7 and R 8 are alkyl of 1 to 4 carbon atoms optionally substituted with hydrogen, phenyl or methoxyphenyl group, may be the same or different and R 5 together with R 6 , R 7 is R 8 And a straight chain saturated alkylene group having 2 to 5 carbon atoms and R 9 is alkyl having 1 to 6 carbon atoms optionally substituted with hydrogen or phenyl.

본 발명에 따른 바람직한 화합물에는 R1및/또는 R3가 수소 또는 메톡시그룹인 화합물류, R2및/또는 R4가 수소, 불소 또는 브롬, 메틸, 메톡시, 에톡시, 이소프로폭시, 메틸티오, 니트로, 아미노 또는 아세틸아미노그룹인 화합물류, R5,R6,R7및/또는 R8이 수소, 메틸,에틸, 프로필, 이소프로필, 부틸, 벤질, P-메톡시벤질 또는 페닐프로필그룹인 화합물류와 R5가 R6와 함께 또는 R7이 R8과 함께 에틸렌, 부틸렌 또는 펜틸렌그룹인 화합물류, A 및/또는 B가 에틸렌, 1-메틸-에틸렌, 1-페닐-에틸렌, 프로필렌, 1-또는 3-메틸-프로필렌 또는 부틸렌그룹인 화합물류와 R9은 수소, 메틸, 에틸, 프로필, 이소프로필, 부틸, n-헥실, 벤질, 페닐에틸 또는 페닐프로필그룹인 화합물류이다.Preferred compounds according to the invention include compounds in which R 1 and / or R 3 are hydrogen or methoxy groups, R 2 and / or R 4 is hydrogen, fluorine or bromine, methyl, methoxy, ethoxy, isopropoxy, Compounds which are methylthio, nitro, amino or acetylamino groups, R 5 , R 6 , R 7 and / or R 8 are hydrogen, methyl, ethyl, propyl, isopropyl, butyl, benzyl, P-methoxybenzyl or phenyl Compounds which are propyl groups and compounds in which R 5 together with R 6 or R 7 together with R 8 are ethylene, butylene or pentylene groups, A and / or B is ethylene, 1-methyl-ethylene, 1-phenyl Compounds of ethylene, propylene, 1- or 3-methyl-propylene or butylene groups and R 9 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, n-hexyl, benzyl, phenylethyl or phenylpropyl groups Compounds.

구조식 (I)화합물과 그의 산부가염류는 약학적 활성을 지니고 있으며 특히 부정맥 치료작용을 갖는다.The compound of formula (I) and acid addition salts thereof have pharmacological activity and in particular, arrhythmia treatment.

구조식 (I)인 새로운 화합물은 다음 구조식 (II)인 호모프탈산 유도체 또는 다음 구조식 (IIa)인 상응하는 호모프탈산 유도체와 다음 구조식 (III)인 아민과 반응시켜 제조한다.New compounds of formula (I) are prepared by reacting a homophthalic acid derivative of formula (II) or a corresponding homophthalic acid derivative of formula (IIa) with an amine of formula (III).

Figure kpo00002
Figure kpo00002

상기 구조식에서In the above structural formula

R1,R2,R5와 R6은 상기와 같고R 1 , R 2 , R 5 and R 6 are the same as above

W는 산소 또는 이미노그룹이고W is oxygen or imino group

X는 할로겐원자, 하이드록실 또는 알콕시그룹이고X is a halogen atom, hydroxyl or alkoxy group

A, B와 R9은 상기와 같고A, B and R 9 are the same as above

Y는 아미노 또는 다음 구조식의 그룹이며Y is amino or a group of

Figure kpo00003
Figure kpo00003

R3,R4,R7과 R8은 상기와 같다.R 3 , R 4 , R 7 and R 8 are the same as above.

반응은 용융상태 또는 메틸렌클로라이드, 에틸렌글라이클 또는 톨루엔과 같은 용매존재하에서, 임의로 칼륨-3급-부톡사이드와 같은 염기존재하, 0내지 250℃온도에서 반응을 진행시키나 바람직하기로는 110내지 180℃이다. 특히 바람직한 것은 톨루엔의 비점에서 물분리용 판넬로 반응시키는 것이다.The reaction proceeds in the molten state or in the presence of a solvent such as methylene chloride, ethylene glycol or toluene, optionally in the presence of a base such as potassium tert-butoxide, at a temperature of from 0 to 250 ° C., but preferably from 110 to 180 ° C. to be. Particularly preferred is to react with a water separation panel at the boiling point of toluene.

더우기 구조식 (II)화합물을 구조식 (III)화합물과 반응시킬 때 중간 생성물인 다음 구조식 (IIb)화합물을 분리해내고 이어서 상기 지시된 반응온도에서 원하는 최종생성물로 전환시킨다.Furthermore, when the compound of formula (II) is reacted with the compound of formula (III), the intermediate product of the following formula (IIb) is separated off and then converted to the desired final product at the reaction temperature indicated above.

Figure kpo00004
Figure kpo00004

상기 구조식에서In the above structural formula

R1,R2,R5,R6,R9A,B와 Y는 상기와 같다.R 1 , R 2 , R 5 , R 6 , R 9 A, B and Y are the same as above.

적어도 R5-R9그룹중의 하나가 수소이거나 또는 R1-R4가 하이드록시그룹인 구조식 (I)화합물을 본 발명에 따라 얻으면 이 화합물을 알킬화에 의해 알킬화된 구조식 (I)화합물로 전환시킬 수 있으며 R1-R4중의 적어도 하나가 수소인 구조식 (I)화합물을 얻으면 이 화합물을 니트로화에 의해 구조식 (I)인 니트로 화합물로 전환시킬 수 있으며 니트로화된 화합물은 환원에 의해 아미노화합물로 전환시킬 수 있으며 이어서 아세틸화하여 상응하는 아세틸아미노 아미노 화합물로 전환시킬 수 있다. 알킬화는 상응하는 알킬할라이드 또는 디알킬설페이트로 실시하는 것이 바람직하며 에탄올, 디메틸포름아마이드, 디메틸설폭사이드 또는 헥사메틸-인산 트리아마이드와 같은 용매중에서 탄산칼슘, 수산화나트륨, 나트륨에톡사이드 또는 칼륨 3급-부톡사이드와 같은 염기존재하에서 바람직하며 온도는 20내지 200℃이나, 바람직한 온도는 60내지 160℃이다. R9이 수소인 메틸화될 수 있는 구조식 (I)화합물은 반응혼합물의 비점하에서 포름알데히드/포름산으로 반응하여 또한 메틸화할 수 있다.If at least one of the R 5 -R 9 groups is hydrogen or R 1 -R 4 is a hydroxy group, obtaining a compound of formula (I) converts it to an alkylated structure of formula (I) by alkylation When at least one of R 1 -R 4 is hydrogen, a compound of formula (I) can be converted to a nitro compound of formula (I) by nitration, and the nitrated compound is an amino compound by reduction. Can be converted to acetylation followed by conversion to the corresponding acetylamino amino compound. Alkylation is preferably carried out with the corresponding alkyl halides or dialkylsulfates, which are calcium carbonate, sodium hydroxide, sodium ethoxide or potassium tertiary in a solvent such as ethanol, dimethylformamide, dimethylsulfoxide or hexamethyl-phosphate triamide. It is preferred in the presence of a base such as butoxide and the temperature is 20 to 200 ℃, the preferred temperature is 60 to 160 ℃. Methylated compounds of formula (I) wherein R 9 is hydrogen can also be methylated by reacting with formaldehyde / formic acid under the boiling point of the reaction mixture.

더우기 본 발명에 따른 구조식 (I) 화합물은 필요에 따라 무기 또는 유기산으로 약학적 무독한 산부가염으로 전환시킬 수 있다. 산으로서 예를 들면 염산, 브롬화수소산, 황산, 락트산, 시트르산, 타타르산, 말레인산 또는 푸마르산이 적합하다.Furthermore, the compound of formula (I) according to the present invention can be converted into inorganic or organic acids into pharmaceutically harmless acid addition salts as necessary. Suitable acids are, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, lactic acid, citric acid, tartaric acid, maleic acid or fumaric acid.

출발물질로 사용된 화합물은 문헌에 알려진 기지의 방법 또는 실시예에 기술된 방법에 따라 얻는다. 상기에서 언급된 바와 같이, 구조식 (I)화합물과 그의 산부가염은 약학적으로 유효한 작용을 가졌으며 특히 부정맥 치료작용을 갖는다.Compounds used as starting materials are obtained according to known methods known in the literature or according to the methods described in the examples. As mentioned above, the compound of formula (I) and acid addition salts thereof have a pharmaceutically effective action, in particular, arrhythmia treatment.

부정맥 치료작용을 시험한 화합물의 예를 들면 다음과 같다.Examples of compounds tested for arrhythmia treatment are as follows.

A=비스[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민,A = bis [3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine,

B=비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민,B = bis- [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine,

C=비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-비스]-에틸아민,C = bis- [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -bis] -ethylamine,

D=[2-(3,4-디하이드로-7-메톡시-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3,4-디하이드로-4,4-디메틸)-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민,D = [2- (3,4-Dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3, 4-dihydro-4,4-dimethyl) -1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine,

E=[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에필]-[3-(3,4-디하이드로-7-메톡시-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민,E = [2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -epi]-[3- (3,4-dihydro- 7-methoxy-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine,

F=비스-[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-메틸아민,F = bis- [2- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl] -methylamine,

G=[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민,G = [2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3,4-dihydro- 4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine,

H=[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)프로필]-[4-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-부틸]-아민,H = [3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) propyl]-[4- (3,4-dihydro-4 , 4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -butyl] -amine,

I=비스[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀린)-에틸]-아민,I = bis [2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolin) -ethyl] -amine,

J=[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[4-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-부틸]-아민.J = [2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[4- (3,4-dihydro- 4,4-Dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -butyl] -amine.

[1. 모르모트의 분리해낸, 전기적으로 자극을 준 심장의 왼쪽 심이(心耳)의 유효 불응기에 대한 작용][One. Effect of Mormot's Isolated, Electrically Stimulated Left Heart of the Heart on the Effective Resonance of the Heart]

[방 법][Way]

성별의 구별없이 모르모트를 목에 일격을 가하여 죽인다. 흉부를 절개한 후 심장을 재빨리 제거하여 37℃의 티로이드(Tyrode)용액속에 옮겨 놓는다. 심이를 절개하여 왼쪽심이만을 사용한다. 전기적 자극은 그라스 자극기 S4G로 10-3초 동안의 구(矩)형파 자극과 12V의 자극으로 행해진다. 심이를 NaCl 136.8; KCl2.68; MgCl20.2625; NaH2PO40.417; NaHCO311.9; CaCl21.8(mval/ℓ); 포도당 3g을 함유한 37℃의 티로이드용액중에 현탁시킨다. 용액은 98%의 산소와 2% 탄산가스로 끊임없이 산화시킨다. 수축현상을 힘 전환장치로 측정하여 그라스-폴리그라프(P5)에 기록한다.Mormor is killed by striking a neck, regardless of gender. After the incision in the chest, the heart is quickly removed and transferred to Tyrode solution at 37 ° C. Cut the seam and use only the left seam. Electrical stimulation is performed with a glass stimulator S4G, with a spherical wave stimulus for 10 -3 seconds and a stimulus of 12V. Shims NaCl 136.8; KCl 2.68; MgCl 2 0.2625; NaH 2 PO 4 0.417; NaHCO 3 11.9; CaCl 2 1.8 (mval / L); It is suspended in a 37 ° C thyroid solution containing 3 g of glucose. The solution is constantly oxidized with 98% oxygen and 2% carbon dioxide. Shrinkage is measured with a force converter and recorded in glass-polygraph (P5).

심이는 0.5헤르쯔로 수축을 한다. 최고 박동수를 매 10초마다 자극율을 1헤르쯔씩 증가시켜 측정한다. 측정은 시험약물을 가하기전 매 5분마다 3회 행하고 가한 후 5분과 10분에 측정한다. 측정시간 간격동안의 자극율은 0.5헤르쯔이다. 약물의 효과는 약물을 가한후 5분과 10분의 최고 박동수의 변화를 계산하여서 한다. 약물은 농도를 증가시켜가며 시험하여 용량-반응곡선을 작성하여 EC50을 계산해 낸다.Sims contract at 0.5 hertz. The maximum heart rate is measured by increasing the stimulus rate by 1 hertz every 10 seconds. The measurement is made three times every 5 minutes before the test drug is added and at 5 and 10 minutes after the addition. The stimulus rate during the measurement time interval is 0.5 Hz. The effect of the drug is calculated by calculating the change in the maximum heart rate for 5 and 10 minutes after adding the drug. Drugs are tested at increasing concentrations to create a dose-response curve to calculate the EC 50 .

[원 리][principle]

최고 박동수는 자극율을 증가시켜가며 측정한다. 두번의 자극사이의 기간이 짧을 때 매초마다의 자극으로 앞의 자극에 대한 수축후의 불응기에 해당되어 다음의 자극에 대해서는 반응이 나타나지 않는다. 그래서 최고박동수는 유효한 불응기에 대한 측정이며 최고 박동수를 감소시키는 화합물은 불응기를 길게 연장시키는 화합물이다.Peak beats are measured with increasing stimulation rate. When the period between the two stimuli is short, it is a stimulus every second, which corresponds to the post-contraction refractory to the preceding stimulus, and no response occurs for the next stimulus. Thus, the highest heart rate is a measure of the effective refractory, and the compound that reduces the highest heart rate is one that extends the inferiority.

[결 과][result]

용량-반응극선으로부터 다음의 농도는 최고 박동수를 50%감소시키는 용량이며 이는 그래프로 처리하여 얻은 것이다.The next concentration from the dose-response pole is the dose that reduces the highest heart rate by 50%, which is obtained by treating the graph.

Figure kpo00005
Figure kpo00005

[2. 쥐의 클로로포름으로 유도시킨 심실 세동에 대한 부정맥 치료효과][2. Arrhythmia Treatment Effect on Ventricular Fibrillation Induced by Chloroform in Rats]

[방 법][Way]

쥐를 클로로포름 기체로 포화된 곳에 놓은 후 40분후에 쥐는 마취되어지며 동시에 호흡기관이 멈추고 다시 20초후에는 헐떡거리는 것을 볼 수 있다. 호흡이 완전히 억제되었을 때 쥐를 클로로포름기체가 있는 곳에서 꺼내서 흉부를 절개하고 재빨리 심장을 절단해내어 심장 운동을 조사한다. 흉부를 절개한 후의 1분간은 거의 모든 동물에서 심실세동현상을 볼 수 있거나 이러한 현상이 없는 것일지라도 심장을 건드려서 이 현상을 유발시킬 수 있다.After placing the rat in a saturated area with chloroform gas, the rat is anesthetized 40 minutes later, and the respiratory system is stopped and again gasping after 20 seconds. When breathing is completely suppressed, remove the rat from the presence of chloroform gas, dissecting the chest and quickly cutting the heart to examine cardiac movement. One minute after the incision of the chest, ventricular fibrillation can be seen in almost all animals, or even if it is not present, it can be caused by touching the heart.

부정맥 치료작용을 갖는 화합물로의 전처리는 용량에 따라 심실세동을 보이는 동물의 수를 감소시킨다. 심실세동을 보이는 동물의 수를 50% 감소시키는 용량은 용량-반응-곡선으로 계산하며 표준오차를 계산한다[참조 : Miller, L.C.와 Tainter M.L., Proc. Soc. Exp. Biol. Med. 57, 261(1944).Pretreatment with a compound having an arrhythmic treatment reduces the number of animals showing ventricular fibrillation with dose. A dose that reduces the number of animals with ventricular fibrillation by 50% is calculated as a dose-response-curve and the standard error is calculated. Miller, L.C. and Tainter M.L., Proc. Soc. Exp. Biol. Med. 57, 261 (1944).

실험은 체중이 20내지 25g인 숫컷쥐를 사용한다. 각 용량을 10마리쥐에 대해 시험한다.The experiment uses male rats weighing 20-25 g. Each dose is tested on 10 rats.

약물은 심실세동을 유발시키기 1분전에 정맥 주사한다.The drug is injected intravenously 1 minute before triggering the ventricular fibrillation.

Figure kpo00006
Figure kpo00006

[3. 급성 독성시험][3. Acute Toxicity Test]

문제시 되는 화합물의 급성독성은 경구 또는 정맥주사후 쥐를 사용하여 결정할 수 있다(관찰시간 : 14일).The acute toxicity of the compound in question can be determined using rats after oral or intravenous injection (observation time: 14 days).

LD50은 관찰시간내의 여러 용량투여후의 치사율로부터 계산해낸다(참조 : J. pharmacol. exp. Therap. 66, 99(1949).LD 50 is calculated from mortality after various doses within the observation time (J. pharmacol. Exp. Therap. 66, 99 (1949).

Figure kpo00007
Figure kpo00007

그러므로 본 발명에 따른 구조식 (I)화합물과 그의 약학적 무독염은 특히 심장의 부정맥 치료에 적합하며 약학적 투여는 통상의 약학적 제제인 정제, 코팅점, 현탁액, 좌제 또는 안정제로 다른 활성물질과 임의로 혼합하여 제조된 제제로 할 수 있다. 어른의 일회 복용량은 25내지 50mg이다.Therefore, the compound of formula (I) and the pharmaceutical non-toxic salt thereof according to the present invention are particularly suitable for the treatment of arrhythmias of the heart, and the pharmaceutical administration is a conventional pharmaceutical preparation with tablets, coating points, suspensions, suppositories, or stabilizers and other active substances. It can be made into a formulation prepared by mixing arbitrarily. Adult doses range from 25 to 50 mg.

다음 실시예는 본 발명을 상술한다.The following examples detail the invention.

[실시예 1]Example 1

[비스-[3-3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)프로필]-메틸아민][Bis- [3-3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) propyl] -methylamine]

19g(0.1몰)의 4,4-디메틸-이소크로만-디온-1,3과 3.6g(0.025몰)의 비스-(3-아미노프로필)-메틸아민을 50ml의 글라이콜중에서 4시간동안 180℃로 가열한다. 냉각한 후 150ml의 10% 탄산칼륨용액을 가하고 혼합액의 클로로포름으로 2회 추출하고 클로로포름층을 2회 물로 세척하고 탈수하여 증발시킨다. 잔사를 100ml의 아세톤중에 녹이고 4ml의 아세톤중의 2.9g의 푸마르산용액과 혼합한 후 100ml용량으로 증발 농축하여 생성된 결정을 흡인 여과한다. 물/목탄으로 재결정한 후 8.5g의 무색 생성물을 얻으며 융점은 156내지 158℃이다. 수율 : 65%19 g (0.1 mole) of 4,4-dimethyl-isochroman-dione-1,3 and 3.6 g (0.025 mole) of bis- (3-aminopropyl) -methylamine in 50 ml of glycol for 4 hours Heat to 180 ° C. After cooling, 150 ml of 10% potassium carbonate solution was added, extracted twice with chloroform of the mixed solution, the chloroform layer was washed twice with water, dehydrated and evaporated. The residue was dissolved in 100 ml of acetone, mixed with 2.9 g of fumaric acid solution in 4 ml of acetone, and concentrated by evaporation to 100 ml. The resulting crystals were suction filtered. After recrystallization from water / charcoal, 8.5 g of a colorless product are obtained with a melting point of 156 to 158 ° C. Yield: 65%

[실시예 2]Example 2

[비스-[3-(3,4-디하이드로-7-메톡시-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 1과 유사한 방법으로 22g(0.1몰)의 4,4-디메틸-7-메톡시-이소크로만-디온-1,3-과 50ml의 글라이콜중의 3.3g(0.025몰)의 비스-(3-아미노프로필)-아민으로부터 표제 화합물을 제조한다. 융점 : 220내지 222℃22 g (0.1 mole) of 4,4-dimethyl-7-methoxy-isochroman-dione-1,3- and 3.3 g (0.025 mole) bis in 50 ml of glycol in a similar manner to Example 1 The title compound is prepared from-(3-aminopropyl) -amine. Melting Point: 220 ~ 222 ℃

[실시예 2]Example 2

[비스-[3-(3,4-디하이드로-6,7-디메톡시-4, 4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]메틸아민][Bis- [3- (3,4-dihydro-6,7-dimethoxy-4, 4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] methylamine]

15g(0.06몰)의 4,4-디메틸-6,7-디메톡시-이소크로만-디온-1,3과 2.9g( 0.02몰)의 비스-(3-아미노프로필)-메틸아민을 물분리용 판넬(funnel)이 달린 장치를 사용하여 4시간동안 200ml의 톨루엔중에서 가열하여 끓여준다. 용매를 진공상태에서 증류시키고 잔사를 실리카겔 컬럼으로 정제한다. 원하는 생성물을 함유한 획분을 합하고 증발시키고 잔사를 50ml의 아세톤에 녹인 후 300ml아세톤에 녹인 1.7g의 푸마르산과 혼합시킨다. 용액을 50ml용량으로 증발 농축하고 에테르를 가한다. 약 1시간후에 침전을 흡인여과하고 건조한다.Water separation of 15 g (0.06 mol) of 4,4-dimethyl-6,7-dimethoxy-isochroman-dione-1,3 and 2.9 g (0.02 mol) of bis- (3-aminopropyl) -methylamine Boil by heating in 200 ml of toluene for 4 hours using a device equipped with a funnel. The solvent is distilled off in vacuo and the residue is purified by silica gel column. Fractions containing the desired product are combined, evaporated and the residue is dissolved in 50 ml of acetone and then mixed with 1.7 g of fumaric acid dissolved in 300 ml of acetone. The solution is concentrated by evaporation to 50 ml volume and ether is added. After about 1 hour, the precipitate is suction filtered and dried.

수율 : 77.2%(11.2g)Yield: 77.2% (11.2 g)

융점(푸마르산염) : 110℃Melting Point (Fumarate): 110 ℃

[실시예 4]Example 4

[비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]아민][Bis- [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] amine]

실시예 3과 유사한 방법으로 300ml의 톨루엔중에서 28.5g(0.15몰)의 4,4-디메틸-이소크로만-디온-1,3과 6.5g(0.05몰)의 비스-(3-아미노프로필)-아민으로 제조한다. 에테르성 염산으로 메탄올 중에서 염산염을 침전시킨다.28.5 g (0.15 mol) of 4,4-dimethyl-isochroman-dione-1,3 and 6.5 g (0.05 mol) of bis- (3-aminopropyl)-in 300 ml of toluene in a similar manner to Example 3 Prepared with amines. Hydrochloric acid precipitates in methanol with etheric hydrochloric acid.

수율 : 53.1%(13.6g)Yield: 53.1% (13.6 g)

융점(염산염) : 170내지 172℃Melting Point (HCl): 170 to 172 ℃

[실시예 5]Example 5

[비스-[3-(3,4-디하이드로-6,7-디메톡시-4, 4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴]-프로필]아민][Bis- [3- (3,4-dihydro-6,7-dimethoxy-4, 4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl] -propyl] amine]

실시예 3과 유사한 방법으로 150ml톨루엔중에서 3g(0.012몰)의 4,4-디메틸 -6,7-디메톡시-이소크로만-디온-1,3과 0.72g(0.0055몰)의 비스-(3-아미노프로필)-아민으로부터 제조한다.3 g (0.012 mol) of 4,4-dimethyl-6,7-dimethoxy-isochroman-dione-1,3 and 0.72 g (0.0055 mol) of bis- (3 in 150 ml toluene in a similar manner to Example 3 -Aminopropyl) -amine.

융점 : 215내지 216℃(메탄올/아세톤으로 재결정함)Melting Point: 215 ~ 216 ℃ (Recrystallized from Methanol / Acetone)

상기 실시예 1내지 5에 따라 다음 화합물을 제조한다.According to Examples 1 to 5, the following compounds were prepared.

2-(3,4-디하이드로-7-메톡시-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민2- (3,4-Dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3,4-di Hydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine

융점 : 103내지 105℃Melting Point: 103 ~ 105 ℃

[2-(3,4-디하이드로-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3, 4-디하이드로-7-메톡시-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]메틸아민[2- (3,4-Dihydro-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3, 4-dihydro-7- Methoxy-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] methylamine

융점 : 158℃Melting Point: 158 ℃

[2-(3,4-디하이드로-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3, 4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]아민[2- (3,4-Dihydro-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3, 4-dihydro-4, 4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] amine

융점(푸마린산염) : 205내지 206℃Melting Point (Fumaline): 205 to 206 ℃

비스-[2-(3,4-디하이드로-4,4-디메틸-1, 3-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-아민Bis- [2- (3,4-dihydro-4,4-dimethyl-1,3-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl] -amine

융점(푸마르산염) : 207내지 208℃Melting Point (Fumarate): 207-208 ℃

[실시예 6]Example 6

[비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]에틸아민][Bis- [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] ethylamine]

7.6g(0.04몰)의 4,4-디메틸-이소크로만-디온-1,3과 3.2g(0.02몰)의 비스-(3-아미노프로필)-에틸아민을 물분리용 판넬이 달린 장치를 사용하여 100ml톨루엔중에서 4시간동안 가열 환류시킨다. 반응혼합물을 증발시키고 실리카겔로 컬럼크로마토 그라피하여 정제하여 아세톤/에테르에 녹인 계산량의 푸마르산으로 염을 형성케하여 침전시킨다.7.6 g (0.04 mole) of 4,4-dimethyl-isochroman-dione-1,3 and 3.2 g (0.02 mole) of bis- (3-aminopropyl) -ethylamine Heated to reflux for 4 h in 100 ml toluene. The reaction mixture is evaporated, purified by column chromatography on silica gel, and precipitated by forming a salt with an amount of fumaric acid dissolved in acetone / ether.

수율 : 71%(8.8g)Yield: 71% (8.8 g)

융점(푸마르산염) : ]141내지 142℃Melting Point (Fumarate):] 141 to 142 ℃

[실시예 7]Example 7

[비스-[3-(3,4-디하이드로-7-메톡시-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-에틸아민][Bis- [3- (3,4-Dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl] -ethylamine]

실시예 6과 유사한 방법으로 100ml의 톨루엔중의 8.8g(0.04몰)의 4,4-디메틸-7-메톡시-이소크로만-디온-1,3과 3.2g(0.02몰)의 비스-(3-아미노프로필)-에틸아민으로부터 제조되어진다.In a similar manner to Example 6, 8.8 g (0.04 mole) of 4,4-dimethyl-7-methoxy-isochroman-dione-1,3 and 3.2 g (0.02 mole) bis- () in 100 ml of toluene 3-aminopropyl) -ethylamine.

수율 : 51.4(7g)Yield: 51.4 (7 g)

융점 : 141내지 143℃Melting Point: 141 ~ 143 ℃

[실시예 8]Example 8

[[3-(3, 4-디하이드로-7-메톡시-4, 4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[4-(3,4-디하이드로-7-메톡시-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-부틸]-프로필아민][[3- (3, 4-Dihydro-7-methoxy-4, 4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl]-[4- (3,4 -Dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -butyl] -propylamine]

실시예 3과 유사한 방법으로 150ml의 톨루엔중의 16.5g(0.07몰)의 4,4-디메틸-7-메톡시-이소크로만-디온-1,3과 4.7g(0.24몰)의 N-(3-아미노프로필)-N-(4-아미노부틸)-프로필아민으로부터 제조되어진다.In a manner similar to Example 3, 16.5 g (0.07 mole) of 4,4-dimethyl-7-methoxy-isochroman-dione-1,3 and 4.7 g (0.24 mole) of N- () in 150 ml of toluene Prepared from 3-aminopropyl) -N- (4-aminobutyl) -propylamine.

수율 : 49.2%(7.3g) : 점액성의 기름Yield: 49.2% (7.3 g): viscous oil

분 석 :analysis :

계산치 : C,69.01% H,7.66% N,7.10%Calculated Value: C, 69.01% H, 7.66% N, 7.10%

실측치 : C,69.00% H,7.65% N,7.13%Found: C, 69.00% H, 7.65% N, 7.13%

[실시예 9]Example 9

[비스-[3-(3,4-디하이드로-7-메톡시-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-프로필아민][Bis- [3- (3,4-Dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl] -propylamine]

실시예 6과 유사한 방법으로 150ml의 톨루엔중의 16.5g(0.075몰)의 4,4-디메틸-7-메톡시-이소크로만-디온-1,3과 4.3g(0.025몰)의 비스-(3-아미노프로필)-프로필아민으로부터 제조되어진다.In a manner similar to Example 6, 16.5 g (0.075 moles) of 4,4-dimethyl-7-methoxy-isochroman-dione-1,3 and 4.3 g (0.025 moles) of bis- (in 150 ml of toluene Prepared from 3-aminopropyl) -propylamine.

[실시예 10]Example 10

[[2-(3,4-디하이드로-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[2-(3, 4-디하이드로-6,7-디메톡시-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-메틸아민][[2- (3,4-Dihydro-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[2- (3, 4-dihydro-6 , 7-dimethoxy-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl] -methylamine]

25ml의 물에 녹인 10.4g(0.1몰)의 아황산수소나트륨용액을 교반하며 7.5ml(0.1몰)의 40%포르말린 수용액에 15분 이내에 적가하고 이어서 혼액을 2시간동안 60℃로 가온하고 이 혼액을 24.6g(0.1몰)의 4,4-디메틸-2-(2-메틸아미노-에 틸-1,2,3,4-테트라하이드로-이소퀴놀린-디온-1,3에 가해준다.10.4 g (0.1 mol) of sodium hydrogen sulfite solution dissolved in 25 ml of water was added dropwise to 7.5 ml (0.1 mol) of 40% formalin aqueous solution within 15 minutes, and the mixture was warmed to 60 DEG C for 2 hours, and the mixture was 24.6 g (0.1 mole) of 4,4-dimethyl-2- (2-methylamino-ethyl-1,2,3,4-tetrahydro-isoquinoline-dione-1,3.

2시간동안 50℃로 가열한 후에 혼액을 냉각하고 20ml의 물에 녹인 4.9g(0.1몰)의 시안화나트륨용액을 가한다. 그후에 반응혼합물을 50℃에서 교반해주고 냉각하여 클로로포름으로 2회 추출한다. 추물출을 탈수하고 증발시킨다. 얻어진 26.5g(0.0977몰)의 기름상물질을 200ml의 메탄올성 암모니아중에서 촉매로 라니니켈을 사용하여 5기압, 50℃에서 7시간동안 수소화시킨다. 매우 점성이 큰 기름상물질인 28g의 4,4-디메틸-2-[N-메틸-N-(2-아미노에틸)-아미노에틸]-1,2,3, 4-테트라하이드로-이소퀴놀린-디온-1,3을 얻는다.After heating to 50 ° C. for 2 hours, the mixture is cooled and 4.9 g (0.1 mol) of sodium cyanide solution dissolved in 20 ml of water is added. Thereafter, the reaction mixture was stirred at 50 ° C, cooled, and extracted twice with chloroform. Dehydrate the extract and evaporate. The obtained 26.5 g (0.0977 mol) of oily substance was hydrogenated at 5 atmospheres and 50 DEG C for 7 hours using Ranickel as a catalyst in 200 ml of methanolic ammonia. 28 g of 4,4-dimethyl-2- [N-methyl-N- (2-aminoethyl) -aminoethyl] -1,2,3,4-tetrahydro-isoquinoline- very viscous oily substance Obtain Dion-1,3.

실시예 10과 유사한 방법으로 이렇게 얻어진 5.2g(0.018몰)의 화합물을 100ml의 톨루엔에 녹인 3.75g(0.015몰)의 4,4-디메틸-6,7-디메톡시-이소 크로만-디온-1,3과 반응시킨다.3.75 g (0.015 mole) of 4,4-dimethyl-6,7-dimethoxy-isochroman-dione-1 dissolved in 100 g of toluene in 5.2 g (0.018 mole) of the compound thus obtained in a similar manner to Example 10 React with, 3.

수율 : 51.2%(5.6g)Yield: 51.2% (5.6 g)

융점 : 122내지 123℃(분해)Melting Point: 122-123 ℃ (Decomposition)

[실시예 11]Example 11

[비스-[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-메틸아민][Bis- [2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl] -methylamine]

실시예 10과 유사한 방법으로 100ml의 톨루엔중의 5.8g(0.02몰)의 4,4-디메틸-2-[N-메틸-N-(2-아미노에틸)-아미노에틸]-1,2,3,4-테트라하이드로-이소퀴놀린-디온-1,3으로부터 제조되어진다.5.8 g (0.02 mole) of 4,4-dimethyl-2- [N-methyl-N- (2-aminoethyl) -aminoethyl] -1,2,3 in 100 ml of toluene in a similar manner as in Example 10 , 4-tetrahydro-isoquinoline-dione-1,3.

수율 : 35.5%(3.3g)Yield: 35.5% (3.3 g)

융점 : 106내지 107℃Melting Point: 106 ~ 107 ℃

[실시예 12]Example 12

[[2-(3,4-디하이드로-7-메톡시-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-메틸아민][[2- (3,4-Dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[2- (3,4 -Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl] -methylamine]

실시예 10과 유사한 방법으로 100ml의 톨루엔중의 5.8g(0.02몰)의 4,4-디메틸-2[N-메틸-N-(2-아미노에틸)-아미노에틸]-1,2,3,4-테트라하이드로-이소퀴놀린-디온-1,3과 6.6g(0.03몰)의 4,4-디메틸-7-메톡시-이소코로만-디온-1,3으로부터 제조되어진다.5.8 g (0.02 mole) of 4,4-dimethyl-2 [N-methyl-N- (2-aminoethyl) -aminoethyl] -1,2,3, in 100 ml of toluene in a similar manner as in Example 10 4-tetrahydro-isoquinoline-dione-1,3 and 6.6 g (0.03 mol) of 4,4-dimethyl-7-methoxy-isocoroman-dione-1,3.

[실시예 13]Example 13

[[2-(3,4-디하이드로-7-메톡시-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[2-(3,4-디하이드로-6,7-디메톡시-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-메틸아민][[2- (3,4-Dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[2- (3,4 -Dihydro-6,7-dimethoxy-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl] -methylamine]

실시예 10과 유사한 방법으로 150ml의 톨루엔중의 6.4g(0.02몰) 4,4-디메틸 -7-메톡시-[N-메틸-N-(2-아미노에틸)-아미노에틸]-1,2,3,4-테트라하이드로-이소퀴놀린-디온-1,3과 5g(0.02몰)의 4,4-디메틸-6,7-디메톡시-이소크로만-디온-1,3으로부터 제조되어진다.6.4 g (0.02 mol) 4,4-dimethyl-7-methoxy- [N-methyl-N- (2-aminoethyl) -aminoethyl] -1,2 in 150 ml of toluene in a similar manner as in Example 10 And 3,4-tetrahydro-isoquinoline-dione-1,3 and 5 g (0.02 mole) of 4,4-dimethyl-6,7-dimethoxy-isochroman-dione-1,3.

수율 : 55%(7.3g) 융점 : 118내지 120℃Yield: 55% (7.3g) Melting Point: 118 ~ 120 ℃

[실시예 14]Example 14

[비스-[2-(3,4-디하이드로-7-메톡시-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴-에틸]-메틸아민][Bis- [2- (3,4-Dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl-ethyl] -methylamine]

실시예 10과 유사한 방법으로 200ml의 톨루엔중의 12.8(0.04몰)의 4,4-디메틸-7-메톡시-2-[N-메틸-N-(2-아미노에틸)-아미노에틸]-1, 2, 3, 4-테트라하이드로-이소퀴놀린-디온-1, 3과 13.2g(0.06몰)의 4,4-디메틸-7-메톡시-이소크로만-디온-1,3으로부터 제조되어진다.In a similar manner to Example 10, 12.8 (0.04 mol) of 4,4-dimethyl-7-methoxy-2- [N-methyl-N- (2-aminoethyl) -aminoethyl] -1 in 200 ml of toluene , 2, 3, 4-tetrahydro-isoquinoline-dione-1, 3 and 13.2 g (0.06 mole) of 4,4-dimethyl-7-methoxy-isochroman-dione-1,3 .

수율 : 37.3%(7.8g)Yield: 37.3% (7.8 g)

융점 : 105내지 151℃(아세톤으로 재결정함)Melting Point: 105 ~ 151 ℃ (Recrystallized from Acetone)

[실시예 15]Example 15

[비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

20.8g(0.1몰)의 α,α-디메틸-호모프탈산과 3.6g(0.025몰)의 비스-(3-아미노프로필)-메틸아민을 50ml글라이콜중에서 180℃로 4시간 가열해준다. 반응혼합액을 냉각하고 150ml의 10%탄산칼륨용액과 혼합하고 클로로포름으로 추출한다. 추출물을 물로 세척하고 탈수하여 증발시킨다. 얻어진 잔사를 에테르에 녹이고 염산염은 에테르성 염산으로 생성하여 침전한다.20.8 g (0.1 mole) of α, α-dimethyl-homophthalic acid and 3.6 g (0.025 mole) of bis- (3-aminopropyl) -methylamine are heated to 180 ° C. in 50 ml of glycol for 4 hours. The reaction mixture is cooled, mixed with 150 ml of 10% potassium carbonate solution and extracted with chloroform. The extract is washed with water and dehydrated to evaporate. The obtained residue is dissolved in ether, and hydrochloride is produced by ether hydrochloric acid to precipitate.

수율 : 72.2(9.5g)Yield: 72.2 (9.5 g)

융점(염산염) : 80℃이상Melting point (hydrochloride): 80 ℃ or more

[실시예 16]Example 16

[비스-[3-(3,4-디하이드로-6,7-디메톡시-4, 4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][Bis- [3- (3,4-dihydro-6,7-dimethoxy-4, 4-dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

실시예 3과 유사한 방법으로 200ml의 톨루엔중의 3.5g(0.14몰)의 4,4-디메틸-6,7-디메톡시-이소크로만-디온-1,3과 0.73g(0.005몰)의 비스-(3-아미노프로필)-메틸아민으로부터 제조되어진다. 염산염을 에테르성 염산으로 생성시키며, 에테르용액중에 침전된다.In a similar manner to Example 3, 3.5 g (0.14 mole) of 4,4-dimethyl-6,7-dimethoxy-isochroman-dione-1,3 and 0.73 g (0.005 mole) bis in 200 ml of toluene It is prepared from-(3-aminopropyl) -methylamine. Hydrochloride is produced with etheric hydrochloric acid and precipitated in ether solution.

수율 : 65%(2.1g)Yield: 65% (2.1 g)

융점(염산염) 70℃이상Melting point (hydrochloride) 70 ℃ or more

[실시예 17]Example 17

[비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 1과 유사한 방법으로 19g의 (0.1몰) 4,4-디메틸-이소크로만-디온-1,3과 3.3g(0.025몰)의 비스-(3-아미노프로필)-아민으로부터 제조되어진다.Prepared in a similar manner to Example 1 from 19 g of (0.1 mole) 4,4-dimethyl-isochroman-dione-1,3 and 3.3 g (0.025 mole) of bis- (3-aminopropyl) -amine .

수율 : 58.1%(8.6g)Yield: 58.1% (8.6 g)

융점 : 216℃(메탄올로 재결정)Melting Point: 216 ° C (Recrystallized from Methanol)

[실시예 18]Example 18

[비스-[3-(3,4-디하이드로-7-메톡시-4, 4-디메틸-1,3-디옥소-2(1H) -이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-7-methoxy-4, 4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 3과 유사한 방법으로 30ml의 톨루엔중의 33g(0.15몰)의 4,4-디메틸-7-메톡시-이소크로만-디온-1,3과 6.5g(0.05몰)의 비스-(3-아미노프로필)-아민으로부터 제조되어진다.In a similar manner to Example 3, 33 g (0.15 mole) of 4,4-dimethyl-7-methoxy-isochroman-dione-1,3 and 6.5 g (0.05 mole) of bis- (3 in 30 ml of toluene -Aminopropyl) -amine.

수율 : 64%(18.3g)Yield: 64% (18.3 g)

융점 : 151내지 152℃Melting Point: 151 ~ 152 ℃

[실시예 19]Example 19

[[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2)1H)-이소퀴놀릴)-프로필]-아민][[2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3,4-dihydro-4 , 4-dimethyl-1,3-dioxo-2) 1H) -isoquinolyl) -propyl] -amine]

1.9g의 4,4-디메틸-이소크로만-디온-1,3과 4.7g의 3-(2-아미노-에틸아미노)-프로필아민을 50ml의 에틸렌글라이콜중에서 160℃로 2시간동안 가열해준다. 냉각한 후에 혼액을 물로 희석하고 여러 차례에 걸쳐 클로로포름으로 추출하고 클로로포름층을 물로 세척한 후 증발시킨다. 잔사를 아세톤으로 처리하고 푸마르산염을 아세톤중의 푸마르산으로 생성하여 이 용액중에 침전시킨다.1.9 g of 4,4-dimethyl-isochroman-dione-1,3 and 4.7 g of 3- (2-amino-ethylamino) -propylamine were heated to 160 ° C. in 50 ml of ethylene glycol for 2 hours. Do it. After cooling, the mixture is diluted with water, extracted with chloroform several times, the chloroform layer is washed with water and evaporated. The residue is treated with acetone and fumarate is produced as fumaric acid in acetone and precipitated in this solution.

수율 : 90%(20.8g)Yield: 90% (20.8 g)

융점(푸마르산염) : 205내지 206℃Melting Point (Fumarate): 205-206 ℃

[실시예 20]Example 20

[[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[4-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴-부틸]-아민][[3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-[4- (3,4-dihydro-4 , 4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl-butyl] -amine]

실시예 23과 유사한 방법으로 9.5g의 4,4-디메틸-이소크로만-디온-1,3과 3.1g의 4-(3-아미노-프로필아미노)-부틸아민으로 부터 제조되어진다.In a similar manner to Example 23, it is prepared from 9.5 g of 4,4-dimethyl-isochroman-dione-1,3 and 3.1 g of 4- (3-amino-propylamino) -butylamine.

수율 : 79%(9.6g)Yield: 79% (9.6 g)

융점(푸마르산염) : 90내지 95℃Melting Point (Fumarate): 90-95 ℃

[실시예 21]Example 21

[비스-[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴-에틸]-아민][Bis- [2- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl-ethyl] -amine]

실시예 23과 유사한 방법으로 9.5g의 4,4-디메틸-이소크로만-디온-1,3과 2.1g의 비스-(2-아미노-에틸)-아민으로부터 제조되어진다.In a similar manner to Example 23, it was prepared from 9.5 g of 4,4-dimethyl-isochroman-dione-1,3 and 2.1 g of bis- (2-amino-ethyl) -amine.

수율 : 80%(9g)Yield: 80% (9 g)

융점(푸마르산염) : 207내지 208℃Melting Point (Fumarate): 207-208 ℃

[실시예 22]Example 22

[비스-[2-(3,4-디하이드로-4-메틸-4-에틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-아민][Bis- [2- (3,4-dihydro-4-methyl-4-ethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl] -amine]

실시예 19와 유사한 방법으로 3.9g의 4-메틸-4-에틸-이소크로만-디온-1,3과 0.79g의 비스-(2-아미노에틸)-아민으로부터 제조되어진다. 염산염을 에테르성 염산으로 생성시켜 아세톤에 침전시킨다.In a similar manner to Example 19, it is prepared from 3.9 g of 4-methyl-4-ethyl-isochroman-dione-1,3 and 0.79 g of bis- (2-aminoethyl) -amine. Hydrochloride is produced with etheric hydrochloric acid and precipitated in acetone.

수율 : 35%(1.7g)Yield: 35% (1.7 g)

융점(염산염) : 260℃이상Melting Point (Hylori): Above 260 ℃

분 석 :analysis :

계산치 : C,65.67 H,6.69 N,8.20 Cl,6.92Calculated Value: C, 65.67 H, 6.69 N, 8.20 Cl, 6.92

실측치 : C,65.20 H,6.60 N,7.95 Cl,6.78Found: C, 65.20 H, 6.60 N, 7.95 Cl, 6.78

5.8g의 [2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3,4-디하이드로-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴) -프로필]-암모늄-푸마르산염을 100ml의 디메틸포름아마이드에 녹이고 2.8g의 탄산칼륨과 1.85g의 2-페닐-에틸브로마이드와 혼합하고 4시간동안 가열환류시킨다. 디메틸포름아마이드를 증발시킨 후 클로로포름으로 추출하고 실리카겔로 정제한다(용출제 : 클로로포름/아세톤=19 : 1). 무색기름상인 물질을 얻는다.5.8 g of [2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3,4-dihydro -4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -ammonium-fumarate was dissolved in 100 ml of dimethylformamide and 2.8 g of potassium carbonate and 1.85 g of 2- Mix with phenyl-ethyl bromide and heat reflux for 4 hours. Distilled dimethylformamide, extracted with chloroform and purified by silica gel (eluent: chloroform / acetone = 19: 1). Obtain a colorless oil.

수율 : 55%(3.1g)Yield: 55% (3.1 g)

분 석 :analysis :

계산치 : C,74.31 H,6.95 N,7.43Calculated Value: C, 74.31 H, 6.95 N, 7.43

실측치 : C,74.10 H,7.06 N,7.41Found: C, 74.10 H, 7.06 N, 7.41

[실시예 23]Example 23

[[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[4-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-2-부틸]-아민][[3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-[4- (3,4-dihydro-4 , 4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -2-butyl] -amine]

4.9g의 [4-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-2-부틸]-(3-아미노프로필)-아민(메틸-[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-케톤과 1,3-디아미노-프로판을 팔라듐/목탄 존재하에서 환원하여 제조함)을 5.2g의 4,4-디메틸-이소크로만-디온-1,3과 함께 2시간동안 160℃로 가열시켜 준다. 생성물을 실리카겔로 컬럼크로마토그라피하여 정제하며(용출제 : 처음엔 순수한 클로로포름, 그후에 점차 클로로포름/아세톤의 비율이 9:1에 이를 때까지 아세톤의 양을 증가시킴). 푸마르산염은 실시예 23에 기술된 것과 같은 방법으로 침전시킨다.4.9 g of [4- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -2-butyl]-(3-aminopropyl) -amine (Methyl- [2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl] -ketone and 1,3-diamino-propane Prepared by reduction in the presence of palladium / charcoal) is heated to 160 ° C. for 2 hours with 5.2 g of 4,4-dimethyl-isochroman-dione-1,3. The product was purified by column chromatography on silica gel (eluant: initially pure chloroform, then gradually increasing the amount of acetone until the chloroform / acetone ratio reached 9: 1). Fumarate is precipitated in the same manner as described in Example 23.

수율 : 18%(1.7g)Yield: 18% (1.7 g)

융점(푸마르산염) : 231내지 232℃Melting Point (Fumarate): 231 ~ 232 ℃

[실시예 24]Example 24

[비스-[3-(2,4-디하이드로-4,4-디메틸-7-이소프로필옥시-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (2,4-Dihydro-4,4-dimethyl-7-isopropyloxy-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

4.32g의 4,4-디메틸-7-이소프로필옥시-이소크로만-디온-1,3과 0.66g의 비스-(3-아미노-프로필)-아민을 물 분리용 판넬이 달린 장치를 이용하여 100ml의 톨루엔중에서 1시간동안 끓인다. 톨루엔을 증발시키고 잔사를 실리카겔로 정제한다(용출제 : 클로로포름/에탄올=19:1). 푸마르산염을 실시예 19에 기술된 것과 같은 방법으로 얻는다.4.32 g of 4,4-dimethyl-7-isopropyloxy-isochroman-dione-1,3 and 0.66 g of bis- (3-amino-propyl) -amine were prepared using a device equipped with a water separation panel. Boil in 100 ml of toluene for 1 hour. Toluene is evaporated and the residue is purified by silica gel (eluent: chloroform / ethanol = 19: 1). Fumarate is obtained in the same manner as described in Example 19.

수율 : 11%(1.2g)Yield: 11% (1.2 g)

융점(푸마르산염) : 171 내지 173℃Melting Point (Fumarate): 171-173 ° C

[실시예 25]Example 25

[비스-[3-(3,4-디하이드로-4,4-디메틸-7-브로모-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-7-bromo-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 24와 유사한 방법으로 4.02g의 4,4-디메틸-7-브로모-이소크로만-디온-1,3과 0.66g의 비스-(3-아미노프로필)-아민으로부터 제조된다.In a similar manner to Example 24, it is prepared from 4.02 g of 4,4-dimethyl-7-bromo-isochroman-dione-1,3 and 0.66 g of bis- (3-aminopropyl) -amine.

수율 : 4.5%(0.5g)Yield: 4.5% (0.5 g)

융점(푸마르산염) : 214내지 216℃Melting Point (Fumarate): 214-216 ℃

[실시예 26]Example 26

[비스-[3-(3,4-디하이드로-4, 4-디메틸-7-플루오로-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-dihydro-4,4-dimethyl-7-fluoro-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

1.8g의 4,4-디메틸-7-플루오로-이소크로만-1,3-디온과 0.38g의 비스-(3-아미노프로필)-아민으로부터 실시예 24와 유사한 방법으로 제조되어진다.Prepared in a similar manner to Example 24 from 1.8 g of 4,4-dimethyl-7-fluoro-isochroman-1,3-dione and 0.38 g of bis- (3-aminopropyl) -amine.

수율 : 5.8%(0.31g)Yield: 5.8% (0.31 g)

융점(푸마르산염) : 234내지 236℃Melting Point (Fumarate): 234 ~ 236 ℃

[실시예 27]Example 27

[비스-[3-(3,4-디하이드로-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]아민][Bis- [3- (3,4-dihydro-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] amine]

실시예 30과 유사한 방법으로 2.44g의 이소크로만-1,3-디온과 비스-(3-아미노-프로필)-아민으로 부터 제조되어진다. 염산염은 에테르성 염산으로 아세톤중에서 침전시킨다.In a similar manner to Example 30, it is prepared from 2.44 g of isochroman-1,3-dione and bis- (3-amino-propyl) -amine. Hydrochloride is precipitated in acetone with etheric hydrochloric acid.

수율 : 2.5%(0.17g)Yield: 2.5% (0.17 g)

융점(염산염) : 135내지 140℃Melting Point (HCl): 135-140 ℃

[실시예 28]Example 28

[비스-[3-(3,4-디하이드로-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][Bis- [3- (3,4-Dihydro-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

실시예 24와 유사한 방법으로 15g의 이소크로만-1,3-디온과 비스-(3-아미노프로필)-메틸아민으로 부터 제조되어진다. 염산염은 에테르성 염산으로 아세톤중에서 침전시키고 에탄올로 재결정한다.In a similar manner to Example 24, it is prepared from 15 g of isochroman-1,3-dione and bis- (3-aminopropyl) -methylamine. Hydrochloride is precipitated in acetone with etheric hydrochloric acid and recrystallized from ethanol.

수율 : 32%(13.8g)Yield: 32% (13.8 g)

융점(염산염) : 202 내지 205℃Melting point (hydrochloride): 202 to 205 ° C

[실시예 29]Example 29

[[3-(3, 4-디하이드로-4, 4-디메틸-7-메틸티오-1, 3-디옥소-2(1H)-이소퀴놀릴)프로필]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][[3- (3, 4-Dihydro-4, 4-dimethyl-7-methylthio-1, 3-dioxo-2 (1H) -isoquinolyl) propyl]-[3- (3,4- Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 23의 방법에 따라 3.03g의 [3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-(3-아미노-프로필)-아민과 2.36g의 4,4-디메틸-7-메틸티오-이소크로만-디온-1,3으로부터 제조되어진다. 염산염을 에테르성 염산으로 아세톤중에서 침전시킨다.3.03 g of [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-(3- according to the method of example 23; 2.36 g of 4,4-dimethyl-7-methylthio-isochroman-dione-1,3 with amino-propyl) -amine. Hydrochloride is precipitated in acetone with etheric hydrochloric acid.

수율 : 8.1%(6.45g)Yield: 8.1% (6.45 g)

융점(염산염) : 116℃(74℃부터 반융상태)Melting point (hydrochloride): 116 ℃ (from 74 ℃ semi-melting)

[실시예 30]Example 30

[[3-(3,4-디하이드로-4,4-디메틸-7-하이드록시-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][[3- (3,4-Dihydro-4,4-dimethyl-7-hydroxy-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl]-[3- (3,4 -Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

2.4g의 에틸-2,2-디메틸-2-(2-카복시-4-하이드록시페닐)-아세테이트와 3g의 [3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로 필-(3-아미노-프로필)-메틸아민을 20ml의 에틸렌글라이콜중에서 1.75시간동안 160℃로 가열해준다. 얼음물을 가하고 혼액을 클로로포름으로 추출한다. 증발후 잔사를 실리카겔로 정제하고(용출제 : 클로로포름/에탄올=19:1)염산염을 에테르성 염산으로 아세톤중에서 침전시킨다.2.4 g of ethyl-2,2-dimethyl-2- (2-carboxy-4-hydroxyphenyl) -acetate and 3 g of [3- (3,4-dihydro-4,4-dimethyl-1,3- Dioxo-2 (1H) -isoquinolyl) -propyl- (3-amino-propyl) -methylamine is heated to 160 ° C. for 1.75 h in 20 ml of ethylene glycol. Ice water is added and the mixture is extracted with chloroform. After evaporation, the residue is purified by silica gel (eluent: chloroform / ethanol = 19: 1) and the hydrochloride is precipitated in acetone with etheric hydrochloric acid.

수율 : 64%(3.4g)Yield: 64% (3.4 g)

융점 : 107℃(69℃에서부터 반응상태)Melting Point: 107 ℃ (Reaction from 69 ℃)

[실시예 31]Example 31

[비스-[3-(3,4-디하이드로-4-메틸-4-벤질-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-4-methyl-4-benzyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 19와 유사한 방법으로 4g의 4-메틸-4-벤질-이소크로만-디온-1,3과 0.79g의 비스-(3-아미노프로필)-아민으로부터 제조되어진다.In a similar manner as in Example 19, 4 g of 4-methyl-4-benzyl-isochroman-dione-1,3 and 0.79 g of bis- (3-aminopropyl) -amine were prepared.

수율 : 38%(2.1g)Yield: 38% (2.1 g)

융점(푸마르산염) : 170내지 172℃Melting Point (Fumarate): 170-172 ℃

[실시예 32]Example 32

[비스-[3-(3,4-디하이드로-4-메틸-4n-부틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-4-methyl-4n-butyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 19와 유사한 방법으로 2.75g의 4-메틸-4-n-부틸-이소크로 만-디온-1,3과 0.62g의 비스-(3-아미노프로필)-아민으로부터 제조되어진다.In a similar manner to Example 19, it is prepared from 2.75 g of 4-methyl-4-n-butyl-isochroman-dione-1,3 and 0.62 g of bis- (3-aminopropyl) -amine.

수율 : 25(1g)Yield: 25 (1 g)

융점(푸마르산염) : 141내지 143℃Melting Point (Fumarate): 141 ~ 143 ℃

[실시예 33]Example 33

[[3-(3,4-디하이드로-4,4,6-트리메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][[3- (3,4-Dihydro-4,4,6-trimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-[3- (3,4-dihydro -4,4-Dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 19와 유사한 방법으로 3.03g의 3-(3,4-디하이드로-4,4-디메틸-1,3과 디옥소-2(1H)-이소퀴놀릴)-프로필]-3(아미노프로필)아민과 2.04g의 4,4,6-트리메틸-이소크로만-디온-1,3으로부터 제조되어진다.3.03 g of 3- (3,4-dihydro-4,4-dimethyl-1,3 and dioxo-2 (1H) -isoquinolyl) -propyl] -3 (aminopropyl) in a similar manner to Example 19 ) And 2.04 g of 4,4,6-trimethyl-isochroman-dione-1,3.

수율 : 5.7%(0.3g)Yield: 5.7% (0.3 g)

융점(염산염) : 203℃(145℃로부터 반융상태)Melting point (hydrochloride): 203 ° C (half-melt from 145 ° C)

[실시예 34]Example 34

[[3-(3,4-디하이드로-4-메틸-4-(4-메톡시-벤질)-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)프로필]-아민][[3- (3,4-Dihydro-4-methyl-4- (4-methoxy-benzyl) -1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-[3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) propyl] -amine]

2.4g의 4-메틸-4-(4-메톡시-벤질)-이소크로만-디온-1,3(메틸 2-메틸 -2-(2-메톡시카보닐-페닐)-3-(4-메톡시-페닐)-프로피오네이트를 알카리성 비누화하고 이어서 탈수하여 제조함)과 3g의 [3-(3,4-디하이드로-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-(3-아미노-프로필)-아민을 각각 50ml메 틸렌클로라이드에 녹인 후 혼합한다. 0.5시간동안 실온에서 방치한 후 용매를 증발시키고 잔류하는 아마이드를 0.75시간동안 180℃로 가열하여 폐환시킨다. 푸마르산염을 아세톤으로 침전시킨다.2.4 g of 4-methyl-4- (4-methoxy-benzyl) -isochroman-dione-1,3 (methyl 2-methyl-2- (2-methoxycarbonyl-phenyl) -3- (4 -Methoxy-phenyl) -propionate prepared by alkaline saponification followed by dehydration) and 3 g of [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) ) -Isoquinolyl) -propyl]-(3-amino-propyl) -amine was dissolved in 50 ml of methylene chloride and mixed. After standing at room temperature for 0.5 hours, the solvent is evaporated and the remaining amide is closed by heating to 180 ° C. for 0.75 hours. Fumarate is precipitated with acetone.

수율 : 39%(2.2g)Yield: 39% (2.2 g)

융점(푸마르산염) : 144℃(분해)Melting Point (Fumarate): 144 ℃ (Decomposition)

[실시예 35]Example 35

[[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-2-프로필]-[3-(3, 4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H-이소퀴놀릴)-프로필]-아민][[3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -2-propyl]-[3- (3, 4-dihydro -4,4-dimethyl-1,3-dioxo-2 (1H-isoquinolyl) -propyl] -amine]

실시예 23과 유사한 방법으로 [3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-2-프로필]-(3-아미노-프로필)-아민과 4,4-디메틸 | 이소크로만-디온-1,3으로부터 제조되어진다.In a similar manner as in Example 23, [3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -2-propyl]-(3-amino -Propyl) -amine and 4,4-dimethyl | isochromen-dione-1,3.

융점(푸마르산염) : 168내지 169℃Melting Point (Fumarate): 168 to 169 ℃

[실시예 36]Example 36

[[3-(3,4-디하이드로-4-메틸-4-(3-페닐프로필)-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[3-(4,4-디메틸-1,3-디옥소-3,4-디하이드로-2(1H)-이소퀴놀릴)-프로필]-아민][[3- (3,4-Dihydro-4-methyl-4- (3-phenylpropyl) -1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-[3- (4 , 4-dimethyl-1,3-dioxo-3,4-dihydro-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 34와 유사한 방법으로 3g의 4-메틸-4-(3-페닐-프로필)-이소크로만-디온-1,3과 3.1g의 [3-(3,4-디하이드로-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-(3-아미노프로필)-아민으로부터 제조되어진다.In a similar manner to Example 34, 3 g of 4-methyl-4- (3-phenyl-propyl) -isochroman-dione-1,3 and 3.1 g of [3- (3,4-dihydro-4,4 -Dimethyl-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl]-(3-aminopropyl) -amine.

수율 : 52%(3.7g)Yield: 52% (3.7 g)

융점(푸마르산염) : 158내지 163℃Melting Point (Fumarate): 158-163 ℃

[실시예 37]Example 37

[비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

0.2g의 2,4,4-트리메틸-1,2,3,4-테트라하이드로-이소퀴놀린-디온-1,3을 0.3g의 [3-(3,4-디하이드로-4,4-디메틸-1, 3-디옥소-2(1H)-이소퀴놀릴)-프로필]-(3-아미노-프로필)-아민과 함께 160℃로 4시간동안 가열해주고 반응혼액을 실리카겔 컬럼으로 정제한다. (용출제 : 클로로포름/메탄올=9:1). 염산염은 에테르성 염산으로 메탄올중에서 침전시킨다.0.2 g of 2,4,4-trimethyl-1,2,3,4-tetrahydro-isoquinoline-dione-1,3 was substituted with 0.3 g of [3- (3,4-dihydro-4,4-dimethyl -1, 3-dioxo-2 (1H) -isoquinolyl) -propyl]-(3-amino-propyl) -amine was heated to 160 ° C. for 4 hours and the reaction mixture was purified by silica gel column. (Eluent: chloroform / methanol = 9: 1). Hydrochloride is precipitated in methanol with etheric hydrochloric acid.

수율 : 29%(0.15g)Yield: 29% (0.15 g)

융점(염산염) : 170내지 172℃Melting Point (HCl): 170 to 172 ℃

[실시예 38]Example 38

[비스-[3-(1,2,3,4-테트라하이드로-1,3-디옥소-이소퀴놀린-4-스피로사이클로펜탄-2-일)-프로필]-메틸아민][Bis- [3- (1,2,3,4-tetrahydro-1,3-dioxo-isoquinolin-4-spirocyclopentan-2-yl) -propyl] -methylamine]

실시예 34와 유사한 방법으로 0.85g의 이소크로만-4-스피로사이클로펜탄-디온-1,3과 0.24g의 비스-(3-아미노-프로필)-메틸아민으로부터 제조되어진다.In a similar manner to Example 34, 0.85 g of isochroman-4-spirocyclopentane-dione-1,3 and 0.24 g of bis- (3-amino-propyl) -methylamine are prepared.

수율 : 2.9%(0.07g)Yield: 2.9% (0.07 g)

융점(염산염) : 127내지 132℃Melting Point (HCl): 127-132 ℃

[실시예 39]Example 39

[[2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-(2-페닐에틸)-아민][[2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3,4-dihydro-4 , 4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-(2-phenylethyl) -amine]

5.8g의 [2-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-에틸]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-암모늄-푸마레이트를 100ml의 디메틸포름아마이드에 녹이고 2.8g의 탄산칼슘과 1.85g의 2-페닐-에틸브로마이드와 혼합하고 4시간동안 환류시킨다. 디메틸포름아마이드를 증발시킨후에 물을 가하고 혼합물을 클로로포름으로 추출하고 추출하고 실리카겔로 정제한다(용출제 : 클로로포름/아세톤=19:1). 무색인 기름상 물질을 얻는다.5.8 g of [2- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -ethyl]-[3- (3,4-dihydro -4,4-Dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -ammonium-fumarate was dissolved in 100 ml of dimethylformamide and 2.8 g of calcium carbonate and 1.85 g of 2- Mix with phenyl-ethyl bromide and reflux for 4 hours. After evaporating dimethylformamide, water is added and the mixture is extracted with chloroform, extracted and purified by silica gel (eluant: chloroform / acetone = 19: 1). Obtains a colorless oily substance.

수율 : 55%(3.1g)Yield: 55% (3.1 g)

계산치 : C,74.31 H,6.95 N,7.43Calculated Value: C, 74.31 H, 6.95 N, 7.43

실측치 : C,74.10 H,7.06 N,7.41Found: C, 74.10 H, 7.06 N, 7.41

[실시예 40]Example 40

[비스-[3-(3,4-디하이드로-4,4-디에틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][Bis- [3- (3,4-dihydro-4,4-diethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

2.35g의 비스-[3-(3,4-디하이드로-1,3-디옥소-2(1H)-이소퀴놀릴-프로필]-메틸아민-염산염과 5.42g의 에틸요다이드를 100ml 에탄올중에서 가열 환류 시키고 10ml 물에 녹인 1.08g의 수산화나트륨용액을 적가해준다. 혼액을 60℃에서 1.5시간 더 교반해준 후 용매를 증발 제거하고 물을 가한다. 혼액을 에틸아세테이트로 추출한다. 실리카겔을 충진한 컬럼으로 정제한 후(용출제 : 클로로포름/에탄올=19:1) 염산염을 에테르성 염산으로 아세톤 중에서 침전시킨다.2.35 g bis- [3- (3,4-dihydro-1,3-dioxo-2 (1H) -isoquinolyl-propyl] -methylamine-hydrochloride and 5.42 g ethyl iodide in 100 ml ethanol Heat and reflux and add 1.08 g of sodium hydroxide solution dissolved in 10 ml of water dropwise, stir the mixture further at 60 ° C for 1.5 hours, evaporate the solvent and add water, extract the mixture with ethyl acetate. After purification by column (eluent: chloroform / ethanol = 19: 1) hydrochloride is precipitated in acetone with etheric hydrochloric acid.

수율 : 5.8%(0.17g)Yield: 5.8% (0.17 g)

융점(염산염) : 135 내지 140℃(70℃부터 반응상태)Melting point (hydrochloride): 135 to 140 ° C (reaction state from 70 ° C)

[실시예 41]Example 41

[[3-(3,4-디하이드로-4,4-디메틸-7-에톡시-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][[3- (3,4-Dihydro-4,4-dimethyl-7-ethoxy-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-[3- (3,4 -Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

1.3g의 [3-(3,4-디하이드로-4,4-디메틸-7-하이드록시-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-[3-(3,4-디하이드로-4,4-디메틸-1, 3-2(1H)-이소퀴놀릴)-프로필]-메틸아민을 10ml의 무수에탄올에 녹여서 10ml 무수 에탄올에 녹인 0.06g의 나트륨용액에 가하고 0.42g의 에틸 요오다이드와 혼합한다. 혼합물을 0.5시간동안 환류시키고 동량의 에틸요다이드를 가하고 다시 0.5시간동안 환류시킨다. 생성물을 실리카겔 컬럼으로 정제하고(용출제 : 클로로포름/에탄올=25:1) 염산염을 에테르성 염산으로 아세톤중에서 침전시킨다.1.3 g of [3- (3,4-Dihydro-4,4-dimethyl-7-hydroxy-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-[3- (3 , 4-dihydro-4,4-dimethyl-1,3-2 (1H) -isoquinolyl) -propyl] -methylamine was dissolved in 10 ml of anhydrous ethanol and added to 0.06 g of sodium solution dissolved in 10 ml of anhydrous ethanol. Mix with 0.42 g ethyl iodide. The mixture is refluxed for 0.5 h, the same amount of ethyl iodide is added and refluxed again for 0.5 h. The product is purified by silica gel column (eluent: chloroform / ethanol = 25: 1) and the hydrochloride is precipitated in acetone with etheric hydrochloric acid.

수율 : 35%(0.5g)Yield: 35% (0.5 g)

융점(염산염) : 45℃ 이상Melting point (hydrochloride): 45 ℃ or more

[실시예 42]Example 42

[비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-n-헥실-아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -n-hexyl-amine]

실시예 39와 유사한 방법으로 2.6g의 비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민과 1g의 n-헥실브로마이드로부터 제조되어진다.2.6 g bis- [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine in a similar manner to Example 39 And 1 g of n-hexylbromide.

수율 : 50%(1.7g)Yield: 50% (1.7 g)

융점(푸마르산염) : 137 내지 138℃Melting Point (Fumarate): 137 to 138 ° C

[실시예 43]Example 43

[비스-[3-(1,2,3,4-테트라하이드로-1,3-디옥소-이소퀴놀릴-4-스피로사이클로헥산-2-일)-프로필]-메틸아민][Bis- [3- (1,2,3,4-tetrahydro-1,3-dioxo-isoquinolyl-4-spirocyclohexan-2-yl) -propyl] -methylamine]

실시예 40과 유사한 방법으로 3.6g의 비스-[3-(3,4-디하이드로-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민과 4.0g의 1,5-디브로모펜탄으로부터 제조되어진다.In a similar manner to Example 40, 3.6 g of bis- [3- (3,4-dihydro-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine and 4.0 g of 1 , 5-dibromopentane.

수율 : 2.6%(0.12g)Yield: 2.6% (0.12 g)

융점(염산염) : 183 내지 185℃Melting point (hydrochloride): 183 to 185 ° C

[실시예 44]Example 44

[비스-[3-(3,4-디하이드로-4-이소프로필-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][Bis- [3- (3,4-Dihydro-4-isopropyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

실시예 40과 유사한 방법으로 4.7g의 비스-[3-(3,4-디하이드로-1,3-디옥소-2(1H)-이소퀴놀릴-프로필]-메틸아민과 3.05g의 이소프로필 브로마이드로부터 제조되어진다.In a similar manner to Example 40, 4.7 g of bis- [3- (3,4-dihydro-1,3-dioxo-2 (1H) -isoquinolyl-propyl] -methylamine and 3.05 g of isopropyl Prepared from bromide.

수율 : 2.2%(0.12g)Yield: 2.2% (0.12 g)

융점(염산염) : 204 내지 206℃Melting point (hydrochloride): 204-206 degreeC

[실시예 45]Example 45

[비스-[3-(1,2,3,4-테트라하이드로-1,3-디옥소-이소퀴놀린-4-스피로사이클로프로판-2-일)-프로필]-메틸아민][Bis- [3- (1,2,3,4-tetrahydro-1,3-dioxo-isoquinolin-4-spirocyclopropan-2-yl) -propyl] -methylamine]

실시예 35와 유사한 방법으로 3.6g의 비스-[3-(3,4-디하이드로-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민과 3.3g의 1,2-디브로모에탄이 제조되어진다.In a similar manner to Example 35, 3.6 g of bis- [3- (3,4-dihydro-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine and 3.3 g of 1 , 2-dibromoethane is prepared.

수율 : 3%(0.05g)Yield: 3% (0.05 g)

융점(염산염) : 192내지 196℃Melting Point (HCl): 192 ~ 196 ℃

[실시예 46]Example 46

[비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-(3-페닐프로필)-아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-(3-phenylpropyl) -amine]

1.8g의 3-페닐-브로모프로판과 20ml 물에 녹인 0.96g의 수산화나트륨 용액을 소량씩 70℃에서 2.56g의 비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디 옥소-2(1H)-이소퀴놀릴)-프로필]-아민의 염산염 용액에 가해준다. 16시간후 혼액을 물에 가하고 에틸아세테이트로 추출한 후 증발시키고 얻어진 잔사를 실리카겔로 정제한다. (용출액 : 클로로포름/에탄올=19:1) 염산염을 에테르성 염산으로 에틸아세테이트중에서 침전시킨다.1.8 g of 3-phenyl-bromopropane and 0.96 g of sodium hydroxide solution dissolved in 20 ml of water were added in small portions at 2.56 g of bis- [3- (3,4-dihydro-4,4-dimethyl-1. To a hydrochloride solution of, 3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine. After 16 hours, the mixture was added to water, extracted with ethyl acetate, evaporated, and the residue was purified by silica gel. (Eluate: chloroform / ethanol = 19: 1) Hydrochloride is precipitated in ethyl acetate with etheric hydrochloric acid.

수율 : 4.2%(0.13g)Yield: 4.2% (0.13 g)

융점(염산염) : 135℃Melting Point (HCl): 135 ℃

[실시예 47]Example 47

[비스-[3-(3,4-디하이드로-4,4-디메틸-7-아세트 아미노-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-7-acetamino-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

3.25g의 비스-[3-(3,4-디하이드로-4,4-디메틸-7-아미노- 1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민-트리하이드라이드를 70ml의 무수 아세트산중에서 현탁시키고 실온에서 2시간 동안 교반해준다. 혼액을 얼음에 가하고 암모니아성으로 해준 후 클로로포름으로 추출하고 증발한 후 얻어진 잔사를 실리카겔을 사용한 컬럼크로마토그라피로 정제한다(용출제 : 클로로포름/메탄올=9:1).3.25 g Bis- [3- (3,4-Dihydro-4,4-dimethyl-7-amino-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine-tri The hydride is suspended in 70 ml of acetic anhydride and stirred at room temperature for 2 hours. The mixture was added to ice, made ammonia, extracted with chloroform, evaporated, and the residue was purified by column chromatography using silica gel (eluant: chloroform / methanol = 9: 1).

염산염은 에테르성 염산으로 에탄올중에서 침전시키며 이소프로판올로 재결정한다.Hydrochloride is precipitated in ethanol with etheric hydrochloric acid and recrystallized from isopropanol.

수율 : 54%(1.8g)Yield: 54% (1.8 g)

융점(염산염) : 175℃Melting Point (HCl): 175 ℃

[실시예 48]Example 48

[비스-[3-(3,4-디하이드로-4,4-디메틸-7-아미노-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-7-amino-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylamine]

5.3g의 비스-[3-(3,4-디하이드로-4,4-디메틸-7-니트로-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸암모늄-나이트레이트를 100ml에 메탄올에 녹이고 10ml의 메탄올성 염산과 0.6g의 10% 팔라듐/목탄을 가하고 혼합물을 5기압 수소압, 실온에서 환원시킨다. 촉매를 흡인여과하고 용매를 제거하고 잔사를 물에 처리한다. 용액을 메틸렌클로라이드로 추출하고 암모니아성으로 해준 후 다시 메틸렌클로라이드로 추출한다. 메틸렌클로라이드층을 증발하고 잔사를 에탄올에 녹이고 3염산염을 에테르성 염산으로 침전시킨다.5.3 g bis- [3- (3,4-dihydro-4,4-dimethyl-7-nitro-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylammonium-knight Dissolve the rate in 100 ml of methanol, add 10 ml of methanolic hydrochloric acid and 0.6 g of 10% palladium / charcoal and reduce the mixture at 5 atmospheres of hydrogen pressure and room temperature. The catalyst is suction filtered, the solvent is removed and the residue is treated with water. The solution is extracted with methylene chloride, ammonia and extracted with methylene chloride again. The methylene chloride layer is evaporated, the residue is dissolved in ethanol and the trichloride is precipitated with etheric hydrochloric acid.

수율 : 63%(3.25g)Yield: 63% (3.25 g)

융점(3염산염) : 225℃Melting Point (Trihydrochloride): 225 ℃

[실시예 49]Example 49

[비스-[3-(3,4-디하이드로-4,4-디메틸-7-니트로-2(1H)-이소퀴놀릴)-프로필]-메틸아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-7-nitro-2 (1H) -isoquinolyl) -propyl] -methylamine]

5g의 비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-메틸암모늄-푸마르산염을 50ml의 발연질산에 -20내지 -30℃에서 가해주고 -25℃에서 40분간 교반해준다. 용액을 얼음에 가하고 침전된 질산염을 흡인여과 한다.50 g fuming 5 g of bis- [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -methylammonium-fumarate Add nitric acid at -20 to -30 ℃ and stir at -25 ℃ for 40 minutes. The solution is added to ice and the precipitated nitrate is suction filtered.

수율 : 100%(5.3g)Yield: 100% (5.3 g)

융점(질산염) : 135℃Melting Point (Nitrate): 135 ℃

[실시예 50]Example 50

[비스-[3-(3,4-디하이드로-4,4-디메틸-7-니트로-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-7-nitro-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 53과 유사한 방법으로 10g의 비스-[3-(3,4-디하이드로-4,4-디메 틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민의 염산염으로부터 제조되어 진다.10 g bis- [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine in a similar manner to Example 53 It is prepared from hydrochloride.

수율 : 83%(10.2g)Yield: 83% (10.2 g)

융점(질산염) : 197℃Melting Point (Nitrate): 197 ℃

[실시예 51]Example 51

[비스-[3-(3,4-디하이드로-4,4-디메틸-7-아미노-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민][Bis- [3- (3,4-Dihydro-4,4-dimethyl-7-amino-1, 3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine]

실시예 48과 유사한 방법으로 비스-[3-(3,4-디하이드로-4,4-디메틸-7-니트로-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-암모늄-니트레이트로부터 제조되어진다.Bis- [3- (3,4-Dihydro-4,4-dimethyl-7-nitro-1,3-dioxo-2 (1H) -isoquinolyl) -propyl]-in a similar manner to Example 48 Prepared from ammonium-nitrate.

수율 : 41%(1g) (일 염산염)Yield: 41% (1 g) (monohydrochloride)

융점(1 염산염) : 300℃ 이상 (285℃부터 반응상태)Melting Point (monohydrochloride): 300 ℃ or higher (reaction state from 285 ℃)

[실시예 52]Example 52

[비스-[3-(3,4-디하이드로-4,4,-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-벤질아민][Bis- [3- (3,4-Dihydro-4,4, -dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -benzylamine]

실시예 46과 유사한 방법으로 5.12g의 비스-[3-(3,4-디하이드로-4,4-디메틸-1,3-디옥소-2(1H)-이소퀴놀릴)-프로필]-아민의 염산염과 1.75g의 벤질브로마아디로부터 염기인 나트륨 에폭사이드를 사용하여 제조되어 진다.5.12 g bis- [3- (3,4-dihydro-4,4-dimethyl-1,3-dioxo-2 (1H) -isoquinolyl) -propyl] -amine in a similar manner to Example 46 Hydrochloride and 1.75 g of benzyl bromadi are prepared using the base sodium epoxide.

수율 : 65%(3.7g)Yield: 65% (3.7 g)

융점 : 108℃Melting Point: 108 ℃

Claims (1)

다음 구조식 (II)인 호모프탈산 유도체 또는 다음 구조식 (IIa)인 상응하는 호모프탈산 유도체와 다음 구조식 (III)인 아민과 반응시키고 필요에 따라 R5-R9그룹중의 적어도 하나가 수소 또는 R1-R4중의 적어도 하나가 하이드록시 그룹인 생성물을 알킬화시켜 상응하는 알킬화된 화합물을 만들거나 R1-R4중의 적어도 하나가 수소인 생성물을 니트로화 시킨후 이니트로화합물을 환원시켜 상응하는 아미노화합물로 전환하고 이 아미노 화합물을 아세틸화하여 상응하는 아세틸아미노 화합물로 전환시킴을 특징으로하는 구조식 (I)의 화합물 및 이의 산부가염의 제조방법.Reacting a homophthalic acid derivative of the following structural formula (II) or a corresponding homophthalic acid derivative of the following structural formula (IIa) with an amine of the following structural formula (III) and optionally at least one of the R 5 -R 9 groups is hydrogen or R 1 Alkylation of a product wherein at least one of -R 4 is a hydroxy group to form the corresponding alkylated compound or nitration of a product wherein at least one of R 1 -R 4 is hydrogen and then reduction of the initro compound to the corresponding amino compound A process for the preparation of a compound of formula (I) and acid addition salts thereof, characterized in that for converting to and acetylating this amino compound to convert it to the corresponding acetylamino compound.
Figure kpo00008
Figure kpo00008
Figure kpo00009
Figure kpo00009
상기 구조식에서 A와 B는 임의로 메틸 또는 페닐그룹으로 치환된 탄소수 2 내지 4인 직쇄 포화알킬렌그룹이며 같거나 서로 다를 수 있고, R1,R2,R3및 R4는 수소, 불소, 염소 또는 브롬, 하이드록시, 아미노, 니트로 또는 아세틸 아미노그룹, 탄소수 1내지 3인 알킬, 알콕시 또는 알킬티오그룹이며, 같거나 서로 다를 수 있고 R5,R6,R7과 R8는 수소, 임의로 페닐 또는 메투시 페닐로 치환된 탄소수 1내지 4인 알킬이며, 같거나 서로 다를 수 있고 R5는 R6와 함께, R7은 R8과 함께 탄소수 2내지 5인 직쇄포화 알킬렌이며 R9은 수소 또는 임의로 페닐로 치환된 탄소수 1내지 6인 알킬이고 W는 산소 또는 아미노그룹이고 X는 할로겐, 하이드록시 또는 알콕시그룹이고 Y는 아미노 또는 다음구조식 그룹이다.In the above structural formula A and B is a straight chain saturated alkylene group having 2 to 4 carbon atoms optionally substituted with methyl or phenyl group and may be the same or different from each other, R 1 , R 2 , R 3 and R 4 are hydrogen, fluorine, chlorine Or bromine, hydroxy, amino, nitro or acetyl amino group, alkyl, alkoxy or alkylthio group having 1 to 3 carbon atoms, which may be the same or different and R 5 , R 6 , R 7 and R 8 are hydrogen, optionally phenyl or is an alkyl group having 1 to 4 carbon atoms substituted with methoxy perspective phenyl, be the same or different from one another and R 5 together with R 6, R 7 is R 8 and with 2 to 5 carbon atoms of straight-chain saturated alkylene, and R 9 is hydrogen Or alkyl having 1 to 6 carbon atoms optionally substituted with phenyl, W is an oxygen or amino group, X is a halogen, hydroxy or alkoxy group and Y is an amino or the following structural group.
Figure kpo00010
Figure kpo00010
KR7601728A 1976-07-15 1976-07-15 Process for preparing homophthalimides KR800000906B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7601728A KR800000906B1 (en) 1976-07-15 1976-07-15 Process for preparing homophthalimides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7601728A KR800000906B1 (en) 1976-07-15 1976-07-15 Process for preparing homophthalimides

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1019800000825A Division KR800001703B1 (en) 1980-02-28 1980-02-28 Process for preparing homophtalimides
KR1019800000824A Division KR800001702B1 (en) 1980-02-28 1980-02-28 Process for preparing homophthalimides

Publications (1)

Publication Number Publication Date
KR800000906B1 true KR800000906B1 (en) 1980-09-10

Family

ID=19202479

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7601728A KR800000906B1 (en) 1976-07-15 1976-07-15 Process for preparing homophthalimides

Country Status (1)

Country Link
KR (1) KR800000906B1 (en)

Similar Documents

Publication Publication Date Title
US3585198A (en) Homopyrimidazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US3950343A (en) Pyrroloisoquinoline derivatives
JPS6072891A (en) Pyrimido(4,5-g)quinoline and intermediate
US3978066A (en) Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
GB1566307A (en) Indole derivatives of amides and amino esters and process for their manufacture
US4001248A (en) N-cycloalkylmethyl decahydroisoquinolines
US4001247A (en) 1-ethyl 3a-(substituted-phenyl) decahydroisoquinoline
US3632587A (en) Piperazino methyl isatinylidine 3 acetates
US3850921A (en) Derivatives of 2,3-norbornanedicarboxamide
NO833217L (en) ISOQINOLINE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE
FI60562C (en) BIS-HOMOFTALIMIDOALKYLAMINER FRAMSTAELLNING AV ANTIARYTMISKA VERKANDE
KR800000906B1 (en) Process for preparing homophthalimides
CA1100136A (en) 4a-aryl octahydro-1h-2-pyrindines
US3452026A (en) Substituted 1,2,3,4-tetrahydroquinolines
US3518270A (en) 6,7,12,13 - tetrahydro - 6,12 - imino - 5h - benzo(5,6)cyclooct(1,2 - b)indole derivatives and process for their production
US3546227A (en) 2,3-dihydro-1h-benz(d,e)isoquinoline carboxamidines
US4143143A (en) Substituted imidazo[5,1-a]isoquinolines
FI61868B (en) FRAMEWORK FOR THERAPEUTIC ADJUSTMENT OF THERAPEUTIC EQUIPMENT 2-PHENYLBICYCLOOKTAN- OCH OCTENDERIVAT
US3067203A (en) Tetrahybroisqquinoline derivatives
US4438121A (en) Isoquinoline amidoxime derivatives
US4029796A (en) Novel N-cycloalkylmethyl decahydroisoquinolines for producing opiate-like analgesia
KR800001702B1 (en) Process for preparing homophthalimides
Petterson et al. Arenediazonium ions. II. Synthesis of several phenanthridines and a quinazoline from ortho-substituted arenediazonium salts and organic nitriles
US4194044A (en) Process for preparing 3-phenoxy morphinans